<DOC>
	<DOCNO>NCT01389700</DOCNO>
	<brief_summary>Primary Objective : - To determine pharmacokinetics ( PK ) single intravenous ( IV ) dose SAR279356 administer intensive care unit ( ICU ) patient mechanical ventilation Secondary Objectives : - To determine safety tolerability SAR279356 - To evaluate pharmacodynamics ( PD ) immunogenicity SAR279356 - Exploratory efficacy SAR279356 prevention bacterial infection</brief_summary>
	<brief_title>Pharmacokinetics , Pharmacodynamics Safety Evaluation SAR279356 Intensive Care Unit Mechanically Ventilated Patients</brief_title>
	<detailed_description>Total study duration ( screen last follow-up visit ) 91 day break follow : - Screening : 1 day prior dose ; - Treatment period : one IV injection Day 1 ; - Follow-up period : 90 day</detailed_description>
	<criteria>Inclusion criterion : ICU patient mechanical ventilation time randomization Patients legally authorize representative ( LAR ) give write informed consent . Exclusion criterion : Patients &lt; 18 year age ; Documented Pseudomonas infection colonization last 30 day ; Immunocompromised patient Hypersensitivity study drug and/or prior therapy monoclonal antibody ; Patient take investigational drug prohibit therapy study within 1 month 5 halflives , whichever longer ; Patient LAR withdraw consent screening ( start sign informed consent form ) ; Acute liver injury relate criterion time study entry : Pregnant breastfeed woman The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>